Literature DB >> 28959281

Association of Two Polymorphic Codons in P53 and ABCC1 Promoter with Prostate Cancer.

Farinaz Behfarjam1, Jalal Rostamzadeh2, Mohammad Ali Zarei1, Bahram Nikkhoo3.   

Abstract

BACKGROUND: In prostate cancer, mutated p53 alleles typically contain missense single-base substitution in codon 72 that resides within exons 5-8. Stable p53 proteins in tumor cell nuclei have been associated with malignancy. A role of p53 is the regulation of drug transporters like ABCC1 (MRP1) by an effect on promoter region.
OBJECTIVES: The objective of this study was to identify association of mutations of p53 at codon 72 and 282 and promoter region of ABCC1 with increased risks of prostate cancer.
MATERIALS AND METHODS: Formalin fixed, paraffin-embedded malignant tissues of 45 patients and 45 control samples were evaluated. PCR-RFLP using BstUI for codon 72 and HpaII restriction enzyme for codon 282 p53 gene, and G-1666A promoter region of ABCC1 gene was performed. To assess the frequency of these mutations and to detect new mutations in cancerous samples, PCR-SSCP analysis was performed.
RESULTS: The frequencies of CC, GC and GG genotypes of codon 72 of p53 were 33.33%, 46.67% and 20.00% in patients with cancer and 15.56%, 48.89% and 35.55% in controls, respectively. The relative allele frequencies of ABCC1 promoter polymorphism were 60.00% A and 40.00% G in patients as opposed to 37.78% for A and 62.22% for G in controls. Genotypic frequencies of p53 codon 72 and G1666A of ABCC1 in patients vs. Controls were statistically significant(p<0.05). The study of these samples with PCR-SSCP displayed some new banding patterns.
CONCLUSIONS: The present findings suggest that CC homozygosity in codon 72 of p53 gene and AA genotype in G-1666A of ABCC1 gene may play a role in combination in prostate cancer and increased susceptibility for this malignancy in the Iranian Kurdish population.

Entities:  

Keywords:  ABCC1; Codon 72 p53; PCR-RFLP; PCR-SSCP; Polymorphism; Prostate cancer

Year:  2015        PMID: 28959281      PMCID: PMC5434987          DOI: 10.15171/ijb.1096

Source DB:  PubMed          Journal:  Iran J Biotechnol        ISSN: 1728-3043            Impact factor:   1.671


  29 in total

1.  p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Ye Xu; Lihua Yao; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Benyao Lin; Youyong Lu; Yuntao Xie
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

2.  An optimal method of DNA silver staining in polyacrylamide gels.

Authors:  Yan-Chuang Han; Cai-Zhu Teng; Zhong-Li Hu; Yun-Chun Song
Journal:  Electrophoresis       Date:  2008-03       Impact factor: 3.535

3.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

Review 4.  Variation in the human TP53 gene affects old age survival and cancer mortality.

Authors:  Diana van Heemst; Simon P Mooijaart; Marian Beekman; Jeroen Schreuder; Anton J M de Craen; Bernd W Brandt; P Eline Slagboom; Rudi G J Westendorp
Journal:  Exp Gerontol       Date:  2005 Jan-Feb       Impact factor: 4.032

Review 5.  Cancer chemoresistance: the relationship between p53 and multidrug transporters.

Authors:  Jason A Bush; Gang Li
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

Review 6.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

7.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

Review 8.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

9.  p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations.

Authors:  Jenni K Peltonen; Henni M Helppi; Paavo Pääkkö; Taina Turpeenniemi-Hujanen; Kirsi H Vähäkangas
Journal:  Head Neck Oncol       Date:  2010-12-15

10.  Functional mechanisms for human tumor suppressors.

Authors:  Wanpeng Sun; Jian Yang
Journal:  J Cancer       Date:  2010-09-15       Impact factor: 4.207

View more
  2 in total

Review 1.  Association of p53 codon 72 Arg>Pro polymorphism and risk of cancer in Iranian population: A systematic review and meta-analysis.

Authors:  Daem Roshani; Alina Abdolahi; Shima Rahmati
Journal:  Med J Islam Repub Iran       Date:  2017-12-27

2.  Association between TP53 gene codon72 polymorphism and prostate cancer risk: A systematic review and meta-analysis.

Authors:  Pei-Zhen Han; De-Hong Cao; Xue-Ling Zhang; Zheng-Ju Ren; Qiang Wei
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.